Evidence map›Paper›PMID 32461524›Full record

ArticleInternal medicine (Tokyo, Japan)2020

Methotrexate-associated Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis Successfully Treated with Brentuximab Vedotin in Combination with Doxorubicin, Vinblastine, and Dacarbazine (BV+AVD).

Yasunobu Sekiguchi, Hiroko Iizuka, Haruko Takizawa, Keiji Sugimoto, Sakura Sakajiri, Tadaaki Inano, Yasutaka Fukuda, Syuichi Shirane, Yasuharu Hamano, Shigeki Tomita and 6 more

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Yasunobu SekiguchiDepartment of Hematology, Juntendo University Urayasu Hospital, Japan.
Hiroko IizukaDepartment of Hematology, Juntendo University Urayasu Hospital, Japan.
Haruko TakizawaDepartment of Hematology, Juntendo University Urayasu Hospital, Japan.
Keiji SugimotoDepartment of Hematology, Juntendo University Urayasu Hospital, Japan.
Sakura SakajiriDepartment of Hematology, Juntendo University Urayasu Hospital, Japan.
Tadaaki InanoDepartment of Hematology, Juntendo University Hospital, Japan.
Yasutaka FukudaDepartment of Hematology, Juntendo University Hospital, Japan.
Syuichi ShiraneDepartment of Hematology, Juntendo University Hospital, Japan.
Yasuharu HamanoDepartment of Hematology, Juntendo University Hospital, Japan.
Shigeki TomitaDepartment of Pathology, Juntendo University Urayasu Hospital, Japan.
Hiroshi IzumiDepartment of Pathology, Juntendo University Urayasu Hospital, Japan.
Mitsuo OkuboDepartment of Transfusion Medicine, Juntendo University Urayasu Hospital, Japan.
Noriko NakamuraDepartment of Clinical Laboratory, Juntendo University Urayasu Hospital, Japan.
Tomohiro SawadaDepartment of Clinical Laboratory, Juntendo University Urayasu Hospital, Japan.
Naoya SekiguchiUrayasu Sekiguchi Clinic, Japan.
Masaaki NoguchiDepartment of Hematology, Juntendo University Urayasu Hospital, Japan.
Juntendo University Urayasu Hospital · JPJuntendo University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 53-year-old woman had been diagnosed with rheumatoid arthritis (RA) in X-6. She was started on methotrexate (MTX) in X-1. She developed a cough, and chest computed tomography showed abnormalities. In X, MTX was discontinued, but the cough persisted. A lung biopsy revealed a diagnosis of nodular sclerosis classic Hodgkin lymphoma (CHL-NS). She was considered to have "other iatrogenic immunodeficiency-associated lymphoproliferative disorders" (OIIA-LPD), MTX-associated Hodgkin lymphoma (MTX-HL). She received six courses of brentuximab vedotin (BV) in addition to AVD (BV+AVD). A complete metabolic response was obtained, and the RA went into remission. This is the fourth reported case of BV+AVD for MTX-HL.

Indexed as

AdultAgedAged, 80 and overAntibiotics, AntineoplasticAntineoplastic Agents, AlkylatingAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsAntirheumatic AgentsArthritis, RheumatoidBrentuximab VedotinDacarbazineDoxorubicinFemaleHodgkin DiseaseHumansAntibiotics, AntineoplasticAntineoplastic Agents, AlkylatingAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicAntirheumatic AgentsBrentuximab VedotinDacarbazineDoxorubicinImmunoconjugatesMethotrexateVinblastineBV+AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine)Hodgkin lymphoma (HL)Methotrexate (MTX)Other iatrogenic immunodeficiency associated lymphoproliferative disorders (OIIA-LPDs)Rheumatoid arthritis (RA)

Identifiers

PMID32461524
PMCPMC7516310
OpenAlexW3030751482

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.